New Delhi, Strides Pharma Science on Wednesday said its unit has received approval from the US health regulator to market a generic drug used in the treatment of gastrointestinal diseases.
Singapore-based Strides Pharma Global Pte. Ltd has received approval from the US Food Drug Administration (USFDA) for the generic version of Sucralfate Oral Suspension, 1 g/10 ml, the drug company said in a statement.
This product is bioequivalent and therapeutically equivalent to AbbVie's Carafate (1 g/10 mL).
Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis and inflammation of the stomach, and to prevent stress ulcers.
According to IQVIA, the market size of Sucralfate Oral Suspension (1 g/10 mL) in the US market was US$124 million.
Shares of the company were trading 6.33 percent higher at Rs 899.75 on BSE.
Singapore-based Strides Pharma Global Pte. Ltd has received approval from the US Food Drug Administration (USFDA) for the generic version of Sucralfate Oral Suspension, 1 g/10 ml, the drug company said in a statement.
This product is bioequivalent and therapeutically equivalent to AbbVie's Carafate (1 g/10 mL).
Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis and inflammation of the stomach, and to prevent stress ulcers.
According to IQVIA, the market size of Sucralfate Oral Suspension (1 g/10 mL) in the US market was US$124 million.
Shares of the company were trading 6.33 percent higher at Rs 899.75 on BSE.
